<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, July 12, 2018 (HealthDay News) — Intratumoral infusion of recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO) can be delivered safely and is tied to higher survival rates than those of historical controls, according to a study published in the July 12 issue of the New England Journal of Medicine<\/i>.<\/p>\n
Annick Desjardins, M.D., from Duke University Medical Center in Durham, N.C., and colleagues conducted a dose-finding and toxicity study among 61 consecutive adult patients who had recurrent World Health Organization (WHO) grade IV malignant glioma. The authors evaluated seven doses of convection-enhanced, intratumoral delivery of PVSRIPO in a dose-escalation phase and a dose-expansion phase.<\/p>\n
Dose level \u22121 (5.0107<\/sup> TCID50<\/sub>) was identified as the phase 2 dose. The researchers found that one dose-limiting toxic effect (a grade 4 intracranial hemorrhage immediately after the catheter was removed) was observed in a patient receiving dose level 5 (1010<\/sup> TCID50<\/sub>). Dose level 5 was de-escalated to reach the phase 2 dose to mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use. Overall, 19 percent of patients had a PVSRIPO-related adverse event of grade 3 or higher in the dose-expansion phase. A plateau of 21 percent overall survival among the patients who received PVSRIPO was reached at 24 months and sustained to 36 months.<\/p>\n “Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry and\/or hold patents related to treating tumors with oncolytic poliovirus.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n